Here’s how Australia could reap the benefits from a stricter regulatory cannabis framework

Unregistered Cannabis Products Fail to Meet TGA Requirements

Unregistered Cannabis Products Fail to Meet TGA Requirements 22nd September, 2020 The TGA’s recent Laboratories Testing Report on routine surveillance of unregistered products supplied to the Australian market via the SAS scheme has revealed that almost one quarter of samples received for testing failed to meet TG093 requirements relating to declarations made to the TGA […]

Q3 2020

FreshLeaf Q3 Market Report Press Release

Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis. Q3 was defined by the greatest drop in product price since early 2016 legalisation of medicinal cannabis products in Australia, as the market has grown 3x year […]

FreshLeaf also has exclusive access to significant datasets generated by some of Australia’s largest medicinal cannabis healthcare companies

FreshLeaf Analytics S3

FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020 Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter low-dose CBD but no smoking, vaping, topicals. Potential $200M market in Australia.FreshLeaf Analytics has welcomed the interim decision today by the Therapeutic Goods Administration (TGA) to make registered low-dose CBD […]

Epidioloex decision PBAC

Epidyolex decision PBAC

TGA Defers Decision to Pay for Epidyolex The Pharmaceutical Benefits Advisory Committee (PBAC), the body that decides whether Australians can have certain medicines subsidised by the taxpayer,  has announced that it will not – for now – subsidize Epidyolex. Epidyolex is a medicinal cannabis product manufactured by UK cannabis giant GW Pharmaceuticals and containing the […]

TGA warns medical cannabis industry about advertising regulation breaches

TGA warns medical cannabis industry about advertising regulation breaches

TGA warns medical cannabis industry about advertising regulation breaches The Therapeutic Goods Administration (TGA), Australia’s health products regulator, has issued a stern warning to the medical cannabis industry that it will soon be ramping up its investigations into alleged breaches of the advertising regulations. This will dovetail with the TGA’s ongoing investigations into product quality […]

FreshLeaf also has exclusive access to significant datasets generated by some of Australia’s largest medicinal cannabis healthcare companies

Australian export laws amended to boost industry

The Export Control Legislation Amendment (Certification of Narcotic Exports) Bill 2020, which passed the Senate on June 17, will allow the Commonwealth Department of Agriculture, Water and the Environment to issue phytosanitary certificates for the export of medicinal cannabis and hemp products. This bill will remove an unintended regulatory barrier which has been hampering some […]

CBD available for sale in pharmacies

Australian government proposes CBD be made available for retail sale

Australian government proposes CBD be made available for retail sale Today the Therapeutic Goods Administration released the Department of Health-initiated proposal to make low-dose CBD oil available for sale in pharmacies as a Schedule 3 drug. The proposed changes would allow the sale of pure CBD oil  (with 2% or less other cannabinoids) to adults […]